Novo Nordisk has officially filed for FDA approval of a higher, 7.2 mg dose of the weight-loss drug Wegovy®. Submitted under the expedited CNPV program, the new dose promises an accelerated review timeline. Phase 3 trial results indicate the 7.2 mg injection could offer significantly greater weight loss potential than the current standard dose.
Novo Nordisk has announced positive headline results from a Phase 2 clinical trial for its investigational drug, amycretin, showcasing its potential to be a next-generation [Read More…]
Novo Nordisk announced today that its blockbuster drug semaglutide failed to slow the progression of early-stage Alzheimer’s disease in two large-scale Phase 3 clinical trials, [Read More…]
Novo Nordisk has unveiled compelling phase 3 data for its next-generation obesity drug, cagrilintide, at the EASD 2025 congress. The novel amylin analogue demonstrated a significant 11.8% average body weight reduction over 68 weeks, far surpassing the placebo group. These promising results have prompted the company to advance cagrilintide into a new dedicated clinical program, RENEW, set to begin later this year.
The landmark STEER study provides the first head-to-head real-world comparison of the cardiovascular benefits of Wegovy® and tirzepatide. In a study of over 21,000 adults with obesity and established cardiovascular disease, Wegovy® (semaglutide 2.4 mg) demonstrated a significantly greater reduction in the risk of heart attack, stroke, and death compared to tirzepatide.
Novo Nordisk’s new studies presented at ESC Congress 2025 highlight semaglutide’s powerful cardiovascular benefits for people with diabetes and obesity, showing substantial reductions in heart attack, stroke, and cardiovascular death risks with Wegovy, Ozempic, and Rybelsus.
Novo Nordisk’s Wegovy has received FDA approval to treat MASH, a serious liver disease linked to obesity and diabetes. This new indication highlights Wegovy’s role in improving liver fibrosis and reversing liver damage alongside lifestyle changes.
Novo Nordisk reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a favorable opinion, suggesting that [Read More…]
Novo Nordisk has applied to the European Medicines Agency (EMA) for a new, increased dosage of Wegovy® (semaglutide), a well-known medication for weight loss, of [Read More…]
Novo Nordisk announced that its leading diabetes medication, Ozempic® (semaglutide), has received a positive recommendation in the EU for an updated label to include peripheral arterial disease.
